Nimodrel Xl (Nifedipine)

Nifedipine acts on the vascular smooth muscle and coronary circulation to manage cardiovascular conditions.

• Hypertension: reduces systemic vascular resistance and lowers arterial pressure.
• Angina pectoris: decreases myocardial oxygen demand and alleviates chest pain episodes.
• Raynaud's phenomenon: improves peripheral blood flow and reduces vasospastic attacks.

• Nifedipine selectively blocks L‑type calcium channels in vascular smooth muscle and cardiac myocytes. By inhibiting calcium influx, it causes arterial vasodilation, reduces peripheral resistance, and lowers cardiac after‑load, which together decrease blood pressure and myocardial oxygen consumption.

Nifedipine may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects

• Headache: mild to moderate intensity.
• Flushing: warmth and redness of the face or neck.
• Peripheral edema: swelling of ankles or lower legs.
• Dizziness or light‑headedness.
• Tachycardia: increased heart rate.
• Nausea or abdominal discomfort.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure.
• Myocardial infarction: rare but reported in high‑risk patients.
• Hepatic dysfunction: elevated liver enzymes.
• Allergic reactions: rash, pruritus, or anaphylaxis.
• Cardiac arrhythmias: irregular heart rhythms.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.

• Blood pressure monitoring: check regularly to avoid excessive hypotension.
• Hepatic impairment: use with caution and adjust dose if needed.
• Concomitant antihypertensives: assess for additive blood‑pressure lowering effects.
• Abrupt discontinuation: taper gradually to prevent rebound hypertension.
• Pregnancy and lactation: evaluate risk‑benefit ratio; limited data available.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nifedipine can interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase nifedipine plasma levels and risk of toxicity.
• Grapefruit juice: potentiates vasodilatory effect and can cause severe hypotension.
• Concurrent use with other potent vasodilators: may lead to additive hypotensive episodes.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic effect.

• Diuretics: can enhance blood‑pressure lowering, requiring dose adjustments.
• Beta‑blockers: may mask tachycardia, necessitating careful heart‑rate monitoring.
• NSAIDs: may blunt antihypertensive response.
• Anticoagulants: monitor for potential changes in bleeding risk.